GMAB

NASDAQ 已收盘

Genmab

51.35 USD
▲+0.38+0.75%
盘后 51.30 -0.10%
2026-11-19
市值
$32.30B
市盈率
45.13
EPS
1.13
股息率
—
52 周区间
23.62 – 59.97
成交量
4.35M
Beta
0.52
目标价
65.01
52W 低 23.6252W 高 59.97
价格走势

公司简介

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n...

关联新闻